Pfizer's second-quarter filing divides its roughly $9.7 billion in expected net savings through 2029 between two programs, showing the role of manufacturing in the drugmaker's cost plans.
The company expects its cost realignment program to provide $6.7 billion in net savings and manufacturing optimization to provide $3 billion, according to the filing.
Pfizer's 2026 outlook accounts for expected revenue effects from certain products losing exclusivity.
Pfizer cited its performance so far this year and continuing cost reductions when it raised its 2026 outlook on Nov. 3, as EconoTimes covered in its earlier report.
